Ozempic Maker’s Stock Plunges 20% After Profit Warning

Written by

in

The New York Times – Business:

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.

This post first appeared in The New York Times – Business. Read the original article.